Clinical Trials

Sponsor: Pennsylvania State University

Sponsor Study ID: BCC015

Study Title: Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

NCT Number: NCT04301843

Phase: II

Protocol Type: Treatment

Age Group: Children

Disease Sites: Soft Tissue

Study Objectives: Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.

---

Study Documents    
(MUSC NetID required for document access)